Ali S Arbab Selected Research

vatalanib (PTK787)

10/2018	CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
9/2017	Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.
1/2016	Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.
1/2016	Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma.
12/2013	Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.
1/2012	Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma.
1/2010	Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ali S Arbab Research Topics

Disease

60	Neoplasms (Cancer) 12/2021 - 12/2003
15	Glioma (Gliomas) 10/2018 - 03/2006
14	Glioblastoma (Glioblastoma Multiforme) 12/2021 - 07/2012
9	Breast Neoplasms (Breast Cancer) 01/2020 - 03/2009
9	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2002
7	Stroke (Strokes) 01/2022 - 01/2012
7	Hypoxia (Hypoxemia) 01/2020 - 09/2008
7	Prostatic Neoplasms (Prostate Cancer) 11/2013 - 01/2008
5	Brain Neoplasms (Brain Tumor) 12/2021 - 01/2005
4	Triple Negative Breast Neoplasms 10/2016 - 01/2014
4	Adenocarcinoma 12/2012 - 01/2011
3	Rheumatoid Arthritis 04/2016 - 06/2007
3	Gliosarcoma 11/2014 - 04/2006
3	Arthritis (Polyarthritis) 03/2014 - 06/2007
3	Carcinoma (Carcinomatosis) 01/2014 - 08/2003
3	Ovarian Neoplasms (Ovarian Cancer) 01/2014 - 11/2011
3	Pancreatic Neoplasms (Pancreatic Cancer) 03/2013 - 12/2010
2	Bone Diseases (Bone Disease) 01/2021 - 08/2020
2	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 03/2010
2	Necrosis 12/2018 - 07/2012
2	Neuroinflammatory Diseases 01/2018 - 01/2018
2	Inflammation (Inflammations) 01/2017 - 05/2008
2	Wounds and Injuries (Trauma) 06/2008 - 07/2006
1	Sepsis (Septicemia) 01/2022
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/2020
1	Bone Resorption 08/2020

Drug/Important Bio-Agent (IBA)

15	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2010
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2018 - 06/2008
10	TriterpenesIBA 03/2013 - 02/2010
9	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2019 - 04/2006
9	bardoxolone methylIBA 03/2013 - 02/2010
9	oleananeIBA 03/2013 - 02/2010
8	erucylphosphocholineIBA 01/2019 - 03/2006
7	vatalanib (PTK787)IBA 10/2018 - 01/2010
7	IronIBA 11/2013 - 08/2003
6	HET0016IBA 09/2017 - 04/2006
6	Oleanolic AcidIBA 03/2013 - 02/2010
6	ferumoxides (Feridex)FDA Link 09/2007 - 10/2002
5	Therapeutic UsesIBA 12/2021 - 09/2013
5	AcidsIBA 01/2019 - 04/2006
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2017 - 06/2008
4	CytokinesIBA 08/2020 - 01/2014
4	Contrast MediaIBA 11/2014 - 01/2010
4	bardoxoloneIBA 11/2011 - 03/2010
4	Protamines (Protamine Sulfate)FDA Link 09/2008 - 03/2006
3	Bevacizumab (Avastin)FDA Link 10/2018 - 01/2012
3	LigandsIBA 01/2018 - 01/2008
3	DNA (Deoxyribonucleic Acid)IBA 04/2016 - 03/2014
3	Tyrosine Kinase InhibitorsIBA 12/2013 - 01/2010
3	ferric oxide (iron oxide)IBA 11/2013 - 08/2003
3	Telomerase (Telomerase Reverse Transcriptase)IBA 03/2013 - 06/2012
3	NF-kappa B (NF-kB)IBA 01/2013 - 01/2008
2	InterleukinsIBA 12/2021 - 12/2018
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 12/2021 - 01/2016
2	salicylhydroxamic acid (SHAM)IBA 11/2020 - 12/2018
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 01/2010
2	AntigensIBA 01/2020 - 08/2017
2	Oncogene Proteins (Oncogene Protein)IBA 01/2020 - 08/2017
2	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2019 - 03/2014
2	Cytochrome P-450 CYP4A (Alkane 1 Monooxygenase)IBA 01/2019 - 04/2006
2	ChemokinesIBA 12/2017 - 10/2017
2	Arachidonic Acid (Vitamin F)IBA 12/2017 - 04/2006
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 01/2010
2	Pharmaceutical PreparationsIBA 01/2016 - 12/2013
2	Vascular Endothelial Growth Factor CIBA 01/2015 - 01/2014
2	CurcuminIBA 01/2015 - 01/2008
2	Gadolinium DTPA (Magnevist)FDA Link 11/2014 - 07/2012
2	von Willebrand FactorIBA 03/2014 - 01/2005
2	celastrol methyl esterIBA 01/2014 - 11/2013
2	Annexin A5IBA 01/2014 - 11/2011
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2014 - 11/2011
2	Sunitinib (Sutent)FDA Link 12/2013 - 01/2012
2	Hormones (Hormone)IBA 11/2013 - 01/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2013 - 02/2010
2	SurvivinIBA 01/2013 - 05/2011
2	sodium-iodide symporter (sodium iodide symporter)IBA 01/2012 - 03/2009
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2012 - 01/2010
2	EstersIBA 01/2011 - 03/2010
2	Platelet-Derived Growth FactorIBA 09/2008 - 06/2008
2	CollagenIBA 06/2008 - 07/2006
1	RNA (Ribonucleic Acid)IBA 01/2022
1	ZincIBA 01/2022
1	ApelinIBA 12/2021
1	CannabidiolIBA 12/2021
1	Immunologic Factors (Immunomodulators)IBA 12/2021
1	P-SelectinIBA 12/2021
1	VaccinesIBA 01/2020
1	Deoxyribonuclease I (Nickase)IBA 01/2020
1	Calcibiotic Root Canal SealerIBA 01/2020

Therapy/Procedure

26	Therapeutics 01/2022 - 01/2008
4	Radiotherapy 12/2021 - 01/2010
3	Drug Therapy (Chemotherapy) 12/2021 - 01/2010
3	Aftercare (After-Treatment) 01/2016 - 11/2005
3	Cell- and Tissue-Based Therapy (Cell Therapy) 06/2008 - 11/2005
2	Intravenous Administration 06/2021 - 09/2013
2	Immunotherapy 01/2021 - 01/2016
2	Chemoprevention 12/2011 - 05/2011
1	Punctures 01/2022
1	Ligation 01/2022
1	Immunomodulation 01/2021